Abstract
Peritoneal metastases (PM) from gastrointestinal and gynecological primaries pose a poor prognosis, but cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers potential survival benefits in select cases. This mini-review outlines key selection criteria: low disease burden (Peritoneal Cancer Index 70), manageable comorbidities, and favorable tumor biology. Completeness of cytoreduction (CC-0/1) is essential, best achieved in highvolume centers. Preoperative assessment via CT, MRI, PET, and laparoscopy guides decisions, with 3-year survival ranging from 5-10% (gastric PM) to 50-60% (ovarian PM). Multidisciplinary expertise optimizes outcomes while minimizing risks.
George Efthymiopoulos, Irina Noskova, John Spiliotis.. Selection Criteria for Cytoreductive Surgery and Hipec for Treatment of Peritoneal Metastases. Global Journal of Translational Medicine 2025 ; 1(1) : 1-3 . DOI: -